As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

PD-L1 TPS ≥50% enriches for anti–PD-(L)1 monotherapy benefit, but threshold-based use risks misclassification due to dynamic expression and inter-assay/inter ...

—A new study of more than 42,000 patients sought to evaluate contemporary trends in testing for biomarkers of non-small cell lung cancer (NSCLC), as well as rates of treatment with ...

Early versus delayed initiation of first-line immune checkpoint inhibitors in metastatic non–small cell lung cancer: A real-world analysis of treatment timing and care context. This is an ASCO Meeting ...

“It's My Wish, We Need This Program”: Qualitative Reflections From People With High-Grade Brain Cancer Consenting to Postmortem Brain Donation Targeted therapy has transformed treatment of non–small ...

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses worldwide and remains a leading cause of cancer-related mortality. Prognostic biomarkers are measurable indicators ...

Recently published Non-small Cell Lung Cancer Market Insights report includes a comprehensive understanding of current ...

Misako Nagasaka, MD, PhD, discusses practical considerations for oncologists implementing subcutaneous (SC) vs intravenous (IV) amivantamab plus lazertinib in the frontline setting for patients with ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a one-size-fits-all approach. Biomarkers serve diagnostic, prognostic, and predictive roles ...

The non-small cell lung cancer market is experiencing robust growth, driven by the increasing incidence of lung cancer and continuous advancements in precision medicine. The introduction of ...